Human Enhancement Drugs Volume Two

1 Reflecting on the current human enhancement drugs categorisation and new directions to consider
Katinka van de Ven, Geoff Bates, Rebecca Askew, Kyle J. D. Mulrooney and Jim McVeigh

PART I Anabolic androgenic steroids and other drugs associated with the development of lean muscle

2 Anabolic androgenic steroid use: epidemiology, risk factors and adverse effects
Gen Kanayama and Harrison G. Pope Jr.

3 On the female image and performance enhancement drugs experience
Jesper Andreasson and April Henning

4 Thinking in systems to understand and respond to harmful AAS use
Geoff Bates and Jim McVeigh

5 The Haarlem experience: an outpatient clinic for users of anabolic steroids
Pim de Ronde and Diederik Smit

6 Becoming allies: combining professional and community-based image and performance enhancing drug harm reduction efforts
Mair Underwood and Dave Crosland

7 “Dropping off the edge of a cliff”: a qualitative exploration of the cessation of anabolic androgenic steroid use in the United Kingdom
Jamie Annakin and Jim McVeigh

PART II Lifestyle drugs

8 Human enhancement drugs in rural settings: exploring the role of place and space in anabolic-andrigenic steroid use
Kyle J. D. Mulrooney and Luke Turnock

9 Contextualising substance use among professionals in Canada
Niki Kiepek

10 Human enhancement modalities: microdosing psychedelics
Dimitris Liokaftos

11 Enhancing sexual and psychosocial experiences: sexualised drug use among men who have sex with men Matthew P. Hibbert, Vivian D. Hope and Lorna A. Porcellato 

12 “Filling the gaps”: understanding oil injection for cosmetic enhancement
Rebekah Brennan

13 Cognitive enhancing drug use in an age of neoliberalism: issues and implications for future potential legislation and policy
John Mann

PART III Sports doping

14 Why anti-doping?
April Henning

15 Involving stakeholders to develop anti-doping education: bridging the gap between research and practice
Cornelia Blank and Elisabeth Happ

16 Seven failed arguments for the inclusion of trans women in elite sport
Ask Vest Christiansen

17 Image and performance enhancing drugs and intersecting populations: recreational Welsh rugby union players and gym users
Luke Thomas Joseph Cox

18 “Doping cases in football are always involuntary”: a critical review
Ekain Zubizarreta and Daniel G. Vasques

Biography

Katinka van de Ven is Principal Consultant at 360Edge and a Research Manager at Hello Sunday Morning. She is also a Visiting Fellow as part of the Drug Policy Modelling Program (DPMP), Social Policy Research Centre (SPRC), UNSW. Katinka is the Editor-in-Chief of Performance Enhancement & Health and the Founder/Director of the Human Enhancement Drugs Network (HEDN).

Kyle J. D. Mulrooney is Senior Lecturer in Criminology and Co-Director of the Centre for Rural Criminology at the University of New England (AU). His research spans diverse areas, including the fields of rural criminology, the sociology of punishment and drug policy, and topics such as crime prevention, policing and enhancement drugs, united by a commitment to understand how social, cultural, and geographic contexts influence the regulation of behaviour and the shaping of justice.

Jim McVeigh holds the post of Evidence in Policy and Practice Lead at Change, Grow, Live (a leading United Kingdom drug treatment and support charity). Prior to this he was Professor in Substance Use and Associated Behaviours in the Department of Sociology at Manchester Metropolitan University, where he retains emeritus professor status. Until 2020 he was the Director of the Public Health Institute at Liverpool John Moores University. He has worked within health/public health for nearly 40 years, qualifying as a Registered General Nurse in 1990 and then working with people who inject drugs, before moving into academia. Jim has built an international reputation within the field of substance use, in particular the use of anabolic steroids and associated human enhancement drug use. He has published extensively on the topic and presented at many influential international conferences. He has contributed to UK National Drug Strategies and advised on legislation and health policy and practice.